Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335867 · ClinicalTrials.gov registry record · Phase 2
Vigabatrin for Cocaine and Alcohol Dependence
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01335867: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT01335867 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01335867, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of vigabatrin at reducing drug and alcohol use in individuals addicted to cocaine and alcohol. Vigabatrin is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
Interventions
- DRUG Placebo
- DRUG Vigabatrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335867
The ClinicalTrials.gov registry entry for NCT01335867 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01335867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01335867 about?
NCT01335867 is a clinical study titled "Vigabatrin for Cocaine and Alcohol Dependence". The purpose of this study is to evaluate the effectiveness of vigabatrin at reducing drug and alcohol use in individuals addicted to cocaine and alcohol. Vigabatrin is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
What is the current status of trial NCT01335867?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2011-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01335867?
The interventions under investigation include: Placebo (DRUG), Vigabatrin (DRUG).
Who is sponsoring clinical trial NCT01335867?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.